Latest Caligan Partners LP Stock Portfolio
$1.50Billion– No. of Holdings #24
Caligan Partners LP Performance:
2026 Q1: 3.44%YTD: 3.44%2025: 136.83%
Performance for 2026 Q1 is 3.44%, and YTD is 3.44%, and 2025 is 136.83%.
About Caligan Partners LP and 13F Hedge Fund Stock Holdings
On 2026-05-15, the fund reported it's updated stock portfolio. In the 13F Holdings report, Caligan Partners LP reported an equity portfolio of $1.5 Billions as of 31 Mar, 2026.
The top stock holdings of Caligan Partners LP are LQDA, , RVMD. The fund has invested 20.4% of it's portfolio in LIQUIDIA CORPORATION and 10.8% of portfolio in ABIVAX SA.
The fund managers got completely rid off INHIBRX BIOSCIENCES INC, RAPT THERAPEUTICS INC (RAPT) and SPRUCE BIOSCIENCES INC (SPRB) stocks. They significantly reduced their stock positions in TANGO THERAPEUTICS INC (TNGX). Caligan Partners LP opened new stock positions in SPYRE THERAPEUTICS INC (AGLE), LB PHARMACEUTICALS INC and SAB BIOTHERAPEUTICS INC (SABS). The fund showed a lot of confidence in some stocks as they added substantially to XENON PHARMACEUTICALS INC (XENE), INVENTIVA SA (IVA) and VOR BIOPHARMA INC (VOR).
The top stock holdings of Caligan Partners LP are LQDA, , RVMD. The fund has invested 20.4% of it's portfolio in LIQUIDIA CORPORATION and 10.8% of portfolio in ABIVAX SA.
The fund managers got completely rid off INHIBRX BIOSCIENCES INC, RAPT THERAPEUTICS INC (RAPT) and SPRUCE BIOSCIENCES INC (SPRB) stocks. They significantly reduced their stock positions in TANGO THERAPEUTICS INC (TNGX). Caligan Partners LP opened new stock positions in SPYRE THERAPEUTICS INC (AGLE), LB PHARMACEUTICALS INC and SAB BIOTHERAPEUTICS INC (SABS). The fund showed a lot of confidence in some stocks as they added substantially to XENON PHARMACEUTICALS INC (XENE), INVENTIVA SA (IVA) and VOR BIOPHARMA INC (VOR).
Caligan Partners LP Equity Portfolio Value
Last Reported on: 15 May, 2026
Caligan Partners LP Annual Return Estimates Vs S&P 500
Our best estimate is that Caligan Partners LP made a return of 3.44% in the last quarter. In trailing 12 months, it's portfolio return was 126.76%.
- Performance
- S&P 500
New Buys
| Ticker | $ Bought |
|---|---|
| spyre therapeutics inc | 44,292,700 |
| lb pharmaceuticals inc | 34,628,700 |
| sab biotherapeutics inc | 30,514,400 |
| opus genetics inc | 27,641,400 |
| mbx biosciences inc | 25,330,400 |
| sensei biotherapeutics inc | 3,971,580 |
| aura biosciences inc | 1,537,790 |
| xilio therapeutics inc | 942,996 |
New stocks bought by Caligan Partners LP
Additions
| Ticker | % Inc. |
|---|---|
| xenon pharmaceuticals inc | 153 |
| inventiva sa | 148 |
| vor biopharma inc | 108 |
| avalo therapeutics inc | 85.47 |
| adma biologics inc | 57.89 |
| tyra biosciences inc | 35.24 |
| revolution medicines inc | 28.73 |
| vaxcyte inc | 20.88 |
Additions to existing portfolio by Caligan Partners LP
Reductions
| Ticker | % Reduced |
|---|---|
| tango therapeutics inc | -35.42 |
Caligan Partners LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| rapt therapeutics inc | -21,825,800 |
| eledon pharmaceuticals inc | -839,527 |
| inhibrx biosciences inc | -25,561,600 |
| spruce biosciences inc | -1,786,980 |
Caligan Partners LP got rid off the above stocks
Sector Distribution
Caligan Partners LP has about 75.7% of it's holdings in Healthcare sector.
- Healthcare
- Others
| Sector | % |
|---|---|
| Healthcare | 75.7 |
| Others | 24.3 |
Market Cap. Distribution
Caligan Partners LP has about 16.1% of it's portfolio invested in the large-cap and mega-cap stocks.
- MID-CAP
- UNALLOCATED
- LARGE-CAP
- MICRO-CAP
- SMALL-CAP
| Category | % |
|---|---|
| MID-CAP | 42 |
| UNALLOCATED | 24.3 |
| LARGE-CAP | 16.1 |
| MICRO-CAP | 10.1 |
| SMALL-CAP | 7.1 |
Stocks belong to which Index?
About 55.9% of the stocks held by Caligan Partners LP either belong to S&P 500 or RUSSELL 2000 index.
- RUSSELL 2000
- Others
| Index | % |
|---|---|
| RUSSELL 2000 | 55.9 |
| Others | 44.1 |
Caligan Partners LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Caligan Partners LP
Caligan Partners LP has 24 stocks in it's portfolio. About 74.3% of the portfolio is in top 10 stocks. ADMA proved to be the most loss making stock for the portfolio. TNGX was the most profitable stock for Caligan Partners LP last quarter.
Last Reported on: 15 May, 2026| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ADMA | adma biologics inc | 2.85 | 4,756,510 | 42,856,200 | added | 57.89 | ||
| AGLE | spyre therapeutics inc | 2.95 | 878,127 | 44,292,700 | new | |||
| ANIK | anika therapeutics inc | 1.39 | 1,435,130 | 20,809,400 | unchanged | 0.00 | ||
| AURA | aura biosciences inc | 0.10 | 229,864 | 1,537,790 | new | |||
| AVTX | avalo therapeutics inc | 1.62 | 1,635,020 | 24,410,900 | added | 85.47 | ||
| ELDN | eledon pharmaceuticals inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| EXEL | exelixis inc | 4.43 | 1,553,260 | 66,619,400 | unchanged | 0.00 | ||
| IVA | inventiva sa | 1.84 | 4,974,910 | 27,610,700 | added | 148 | ||
| LQDA | liquidia corporation | 20.39 | 8,118,890 | 306,407,000 | unchanged | 0.00 | ||
| OCUP | opus genetics inc | 1.84 | 6,075,030 | 27,641,400 | new | |||
| PCVX | vaxcyte inc | 7.97 | 2,060,720 | 119,748,000 | added | 20.88 | ||
| RAPT | rapt therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| RVMD | revolution medicines inc | 10.70 | 1,652,810 | 160,736,000 | added | 28.73 | ||
| SABS | sab biotherapeutics inc | 2.03 | 7,967,210 | 30,514,400 | new | |||
| SNSE | sensei biotherapeutics inc | 0.26 | 126,002 | 3,971,580 | new | |||
| SPRB | spruce biosciences inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| TNGX | tango therapeutics inc | 3.35 | 2,408,800 | 50,392,100 | reduced | -35.42 | ||
| TYRA | tyra biosciences inc | 3.26 | 1,276,970 | 48,907,900 | added | 35.24 | ||
| VOR | vor biopharma inc | 2.29 | 1,925,070 | 34,343,200 | added | 108 | ||
| VRCA | verrica pharmaceuticals inc | 0.32 | 923,910 | 4,887,480 | unchanged | 0.00 | ||